About

Nadim Mahmud, MD, MS, MPH, MSCE, is an Assistant Professor of Medicine (Gastroenterology) at the Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center. He is a Senior Fellow at the University of Pennsylvania Leonard Davis Institute and a Senior Scholar at the Center for Clinical Epidemiology and Biostatistics. Dr. Mahmud's research focuses on clinical epidemiology, with particular attention to hepatology, cardiology, and inflammatory bowel disease. He has developed research resources such as the IM Research Hub for the Internal Medicine residency program at Penn and has contributed to numerous studies on liver disease, cardiovascular health, and infectious diseases. His educational background includes a Bachelor of Science from Yale University, a Master of Public Health from Columbia Mailman School of Public Health, an MD from Stanford University School of Medicine, and a Master of Science in Clinical Epidemiology from the University of Pennsylvania Perelman School of Medicine.

Research topics

• Medicine
• Biology
• Immunology
• Internal medicine
• Cell biology

Selected publications

• The Role of Flavin Mononucleotide in Assessing Liver Viability During Normothermic Regional Perfusion

  American Journal of Transplantation · 2026-01-01

  articleOpen access
  PublisherOA PDFDOI

• Acute-on-chronic liver failure: pathophysiological mechanisms and clinical management

  Nature Reviews Gastroenterology & Hepatology · 2026-01-05 · 4 citations

  article
  PublisherDOI

• Concomitant GLP-1 Receptor Agonist Therapy Is Associated With Significant Weight Reduction In Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten

  Journal of Cardiac Failure · 2026-01-01

  article
  PublisherDOI

• Revisiting Allogeneic Hematopoietic Cell Donor Selection Guidelines: Umbilical Cord Blood in the PTCy Era

  Transplantation and Cellular Therapy · 2026-01-02

  articleSenior author
  PublisherDOI

• Antihypertensive Dosing During Mavacamten Therapy for Obstructive Hypertrophic Cardiomyopathy

  Journal of Cardiac Failure - Intersections · 2026-01-02

  articleOpen access
  PublisherOA PDFDOI

• Feasibility and Target AUC Accuracy of Personalized High Dose Melphalan in Myeloma

  Transplantation and Cellular Therapy · 2025-02-01

  article
  PublisherDOI

• Shaping the future of cell and gene therapy workforce development: training of cell therapy processing personnel - perspectives from the International Society for Cell & Gene Therapy Lab Practices Committee

  Cytotherapy · 2025-04-10 · 6 citations

  article
  PublisherDOI

• Effect of race and socio-economic status in allogeneic STEM cell transplantation. a single center experience.

  Blood · 2025-11-03

  article

  Abstract Background Access to and outcomes after allogeneic hematopoietic cell transplantation (allo-HCT) have been previously associated with race and socioeconomic status (SES), mostly in registry or multicenter studies and with different results. Building on the racial and socioeconomic diversity of our institution's patient population, we retrospectively analyzed how race, individual- and area-level SES influenced transplant outcomes in a uniformly treated cohort. Methods We reviewed 263 adult patients who underwent allo-HCT at the University of Illinois at Chicago between 2012–2023 for any diagnosis other than Sickle Cell Disease. Individual-level SES data included race, Medicaid status, employment, education, relationship status, and receipt of financial aid. Area-level SES indicators (linked to geocoded home address) included Area Deprivation Index (ADI), median household income, poverty rate, and Social Vulnerability Index (SVI), based on 2022 U.S. Census data. Outcomes analyzed included overall survival (OS), graft-versus-host disease-free relapse-free survival (GRFS), chronic GVHD (cGVHD), relapse, and non-relapse mortality (NRM). Demographic, transplant and socioeconomic characteristics were compared across racial groups and by Medicaid status using Chi-squared test or Kruskal-Wallis rank sum test. Kaplan-Meier and cumulative incidence methods were used for univariate analyses; Cox and Fine-Gray models for multivariable analysis. Results The cohort was 43% non-Hispanic White, 21% non-Hispanic Black, 30% Hispanic, and 6% Asian. Medicaid was the primary insurer for 52% of patients; 57% received financial aid. Racial minorities had significantly higher unemployment, Medicaid use, and worse area-level SES indicators (e.g., higher SVI, lower income). Despite these disparities, race was not associated with OS, GRFS, NRM, or relapse. Medicaid status was associated with a higher incidence of cGVHD (p=0.02), but not with OS, GRFS, relapse, or NRM. The 1-year cumulative incidence (CI) of cGVHD was 28% for the Medicaid group compared to 19% for the non-Medicaid group. Among area-level SES variables, poverty rate and SVI were associated with higher cGVHD incidence and worse GRFS, but not with OS or NRM (1-year CI: 34% vs 21% for poverty rate; 1-year CI: 32% vs 22% for SVI). In multivariate analysis, Medicaid remained independently associated with higher risk of cGVHD (HR 1.71; p=0.039). Conclusions In this diverse single-center cohort, race and SES were not associated with survival outcomes after allo-HCT, reflecting equitable care delivery. However, SES disadvantage, particularly Medicaid status, higher poverty, and social vulnerability, was linked to increased cGVHD risk, possibly reflecting challenges with treatment adherence or access to follow-up care. These findings underscore the need for targeted support strategies in socially vulnerable patients and highlight the importance of using both individual- and area-level SES data for better patient characterization.

  PublisherDOI

• Beyond body weight: investigating the impact of body surface area on graft CD34+ cell dosing: a single-center experience

  Cytotherapy · 2025-10-10

  articleOpen accessSenior author

  BACKGROUND AIMS: This retrospective study investigated the impact of dosing CD34+ cells on the basis of body weight, body surface area (BSA) and body mass index (BMI) on neutrophil and platelet engraftment after autologous stem cell transplantation (SCT) in patients with multiple myeloma (MM). METHODS: We performed a retrospective chart review of 114 patients including 97 patients (48 male and 49 female) diagnosed with MM and 17 patients diagnosed with Non-Hodgkin lymphoma. The study categorized subjects on the basis of BMI (<25 and ≥25) and BSA (<1.9 m² and ≥1.9 m²). RESULTS: The findings revealed no significant difference in time to neutrophil engraftment after SCT for different BMI groups, which was on average 11.1 days. However, BSA played a significant role as patients with a BSA ≥1.9 m² exhibited delayed platelet engraftment in contrast to the low BSA group (18.55 days versus 16.42 days, P < 0.05). Furthermore, although CD34+ cell doses were comparable across groups when adjusted for body weight, a BSA-based analysis indicated a greater absolute number of CD34+ cells were administered to patients with BSA ≥1.9 m² (6.07 versus 4.78 cells × 10⁸/m², P < 0.05). By using a multivariate analysis, we showed that for neutrophil engraftment, the best predictive model included age, fat-free mass (FFM) and CD34+ cells (P < 0.1) along with BSA (P = 0.12). For platelet engraftment, the best predictive model included sex and FFM (P < 0.1), with BSA as a significant predictor (P = 0.02). Patients with greater BSA (≥1.9 m²) had a nonsignificantly shorter adjusted time to neutrophil engraftment (LS mean = 10.96) compared with those with lower BSA (<1.9) (LS mean = 11.23). However, greater BSA (≥1.9 m²) was significantly associated with a longer adjusted time to platelet engraftment (LS mean = 18.94) versus lower BSA (<1.9) (LS mean = 16.21). CONCLUSION: Our results highlight that male patients with a high BSA experienced a 4-day delay in platelet engraftment after autologous SCT. This delay emphasizes the need for optimized dosing strategies to enhance post-transplant recovery, particularly in patients with elevated BSA. Shortening the time to hematopoietic engraftment after SCT may significantly reduce hospital stays and lower the risk of infections, bleeding, and transfusion-related complications.

  PublisherOA PDFDOI

• The Effect of Bariatric Surgery on Hypertension Outcomes: A Retrospective Cohort Study

  Journal of Human Hypertension · 2025-08-20

  articleOpen access

  Abstract Metabolic and bariatric surgery (MBS) is an effective treatment for obesity and metabolic syndrome. Evidence regarding the impact of MBS on hypertension outcomes is limited by short-term follow-up. Thus, this retrospective cohort study was designed to compare blood pressure (BP) control, number of antihypertensive medications (AHMs), development of apparent treatment resistant hypertension (ATRH), and remission of hypertension between patients treated with and without MBS. Adults with BMI ≥ 35 kg/m 2 and a new diagnosis of hypertension receiving care within the Veterans Health Administration system from 2000–2019 were included. Generalized estimating equations and time-updated Cox models with inverse probability of treatment weighting to address time-updated confounding were used. Over a median follow-up of 5.1 years, 183702 patients with BMI ≥ 35 kg/m 2 and hypertension were managed medically and 3965 were managed surgically. At baseline, those who underwent MBS were more likely to be women than men (22 vs. 10%). Patients treated surgically demonstrated significantly better BP control over time, with an average 5.4 mm Hg (95% CI 4.9–5.9) lower systolic BP and 1.8 mm Hg (95% CI 1.5–2.1) lower diastolic BP. Compared to patients treated medically, those who received MBS had 32% higher likelihood of complete AHM discontinuation (95% CI 1.23–1.42). Patients treated with MBS were 14% less likely to develop ATRH (95% CI 0.78–0.95). Overall, among patients with obesity and hypertension, treatment with MBS was associated with durably improved BP control compared to medical management, including lower systolic and diastolic BPs, higher AHM cessation, and lower rates of ATRH.

  PublisherOA PDFDOI

Recent grants

• NIH Grant R01HL130760

  NIH · $1.3M · 2020

• Production of Cultured Red Blood Cells

  NIH · $6.5M · 2015–2029

Frequent coauthors

• Damiano Rondelli

  St. Jude Children's Research Hospital

  231 shared

• Pritesh Patel

  150 shared

• David Peace

  University of Illinois Chicago

  91 shared

• Dolores Mahmud

  Illinois College

  84 shared

• Karen Sweiss

  University of Illinois Chicago

  77 shared

• Santosh L. Saraf

  University of Illinois Chicago

  72 shared

• John G. Quigley

  University of Illinois Urbana-Champaign

  64 shared

• Annie Oh

  53 shared

Education

• PhD, Hematology/Oncology

  Mie University

  1996

• MBBS (MD)

  Chittagong Medical College

  1989

Awards & honors

• Senior Fellow, University of Pennsylvania Leonard Davis Inst…
• Senior Scholar, Center for Clinical Epidemiology and Biostat…